Incomplete septal cirrhosis after high-dose methylprednisolone therapy and regression of liver injury

2014 ◽  
Vol 35 (2) ◽  
pp. 674-676 ◽  
Author(s):  
Elisabetta Grilli ◽  
Vincenzo Galati ◽  
Nicola Petrosillo ◽  
Franca Del Nonno ◽  
Andrea Baiocchini
Keyword(s):  
Liver Injury ◽  
High Dose ◽  
High Dose Methylprednisolone ◽  
Incomplete Septal Cirrhosis

Toxic liver injury after high-dose methylprednisolone in people with multiple sclerosis

2018 ◽  
Vol 25 ◽  
pp. 43-45 ◽  
Author(s):  
Ivan Adamec ◽  
Ivan Pavlović ◽  
Tin Pavičić ◽  
Berislav Ruška ◽  
Mario Habek
Keyword(s):  
Multiple Sclerosis ◽  
Liver Injury ◽  
High Dose ◽  
High Dose Methylprednisolone ◽  
Toxic Liver Injury

scholarly journals Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis

2015 ◽  
pp. bcr2015210722 ◽  
Author(s):  
Ana Torres Oliveira ◽  
Sandra Lopes ◽  
Maria Augusta Cipriano ◽  
Carlos Sofia
Keyword(s):  
Multiple Sclerosis ◽  
Liver Injury ◽  
High Dose ◽  
High Dose Methylprednisolone

High-dose methotrexate-induced reversible grade 4 hyperbilirubinaemia and transaminitis in an adolescent with Burkitt Leukaemia

2021 ◽  
Vol 14 (1) ◽  
pp. e237512
Author(s):  
Sanjeev Khera ◽  
Randhir Ranjan ◽  
Sateesh Ramachandran ◽  
Ajay Beriwal
Keyword(s):  
Liver Injury ◽  
Clinical Significance ◽  
Short Latency ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Drug Induced ◽  
Common Cause ◽  
Drug Induced Liver Injury ◽  
Dose Methotrexate

Symptomatic drug-induced liver injury (DILI) is an uncommon problem. Direct DILI is dose-related, predictable with short latency (hour to days) and is generally associated with transient and reversible transaminitis without jaundice. Antimetabolites including methotrexate are a common cause for direct DILI. Hepatotoxicity associated with high-dose methotrexate (HD-MTX) is generally transient and includes reversible elevation of transaminase in up to 60% and associated hyperbilirubinaemia (≤grade 2) in 25% of courses and therefore is of no clinical significance. Severe grades of DILI with HD-MTX (grade ≥4) are extremely rare. We describe an adolescent with Burkitt leukaemia who had reversible grade 4 DILI including hyperbilirubinaemia postfirst course of HD-MTX. Rechallenge with two-third dose of HD-MTX in subsequent chemotherapeutic cycle did not cause recurrence of DILI.

Letter to the editor: High-dose methylprednisolone in resistant and relapsed children with acute lymphoblastic leukemia

1994 ◽  
Vol 22 (1) ◽  
pp. 68-69 ◽  
Author(s):  
GÖNÜL Hiçsönmez ◽  
Şinasi Özsoylu ◽  
Neşe Onat ◽  
Zamani Vahide Prozorova ◽  
Fatma Gümrük ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
High Dose ◽  
Letter To The Editor ◽  
High Dose Methylprednisolone

Ranscriptome Analysis Reveals the Molecular Mechanism of Yiqi Rougan Decoction in Reducing CCl4-induced Liver Fibrosis in Rats

2021 ◽  
Author(s):  
Yu Xiong ◽  
Jinyuan Hu ◽  
Chen Xuan ◽  
Jiayu Tian ◽  
Kaiyue Tan ◽  
...  
Keyword(s):  
Protein Kinase ◽  
Liver Fibrosis ◽  
Liver Injury ◽  
Molecular Mechanism ◽  
Treatment Strategies ◽  
Specific Treatment ◽  
Mitogen Activated Protein Kinase ◽  
Signalling Pathways ◽  
High Dose ◽  
Peroxisome Proliferator

Abstract BackgroundLiver fibrosis develops from various chronic liver diseases, and there is currently a lack of specific treatment strategies. Yiqi Rougan decoction (YQRG) is a traditional Chinese medicine that has shown durative effects in the treatment of liver fibrosis; however, the mechanism associated with YQRG-related improvements in liver fibrosis remains to be experimentally determined. This study evaluated the therapeutic effect of YQRG on carbon tetrachloride (CCl4)-induced liver fibrosis in rats and its molecular mechanism. MethodsWe used low-, medium-, and high-dose YQRG to treat CCl4-induced liver fibrosis in rats, followed by assessment of liver injury and fibrosis according to liver appearance, body weight, liver mass index, histopathologic examination, and serum testing. Additionally, we performed transcriptome analysis using RNA-sequencing (RNA-seq) technology, including cluster, Gene Ontology (GO), and pathway analyses, to identify differentially expressed genes (DEGs), and protein and gene expression were detected by immunofluorescence (IFC), western blot, and real-time quantitative PCR. ResultsThe results showed that YQRG effectively alleviated CCl4-induced liver injury and fibrosis in rats, including observations of improved liver function, decreased activity of hepatic stellate cells (HSCs), and decreased extracellular matrix (ECM) deposition. Moreover, we identified downregulated and upregulated DEGs in the model group relative to the control and YQRG-treated groups, with GO analysis revealing their enrichment in biological processes, such as endoplasmic reticulum stress (ERS), apoptosis, and autophagy. Furthermore, pathway analysis showed that YQRG treatment downregulated the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/Akt (PI3K/AKT) signalling pathways and upregulated other signalling pathways, including those related to peroxisome proliferator-activated receptors(PPAR) and AMP-activated protein kinase(AMPK), with these finding subsequently verified experimentally. ConclusionThese findings showed that YQRG improved CCl4-induced liver fibrosis through multiple mechanisms and pathways, offering critical insight into the YQRG-related therapeutic mechanism and promoting further research into its potential application.

Sign in / Sign up

Export Citation Format

Share Document